Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Inclusion: * Patients with histologic proof of adenocarcinoma of the prostate and must have progressed on conventional hormonal therapy. * Patients must have bone metastases which can be demonstrated by bone scans. Lytic bone lesions should be considered for biopsy if there is a clinical suspicion of histologic conversion to small cell carcinoma. * Patients must have evidence of progression of disease. PSA- progression is defined as 2 consecutive increments in PSA (an absolute change of at least 1ng/mL) over 4 weeks. An increase by 25% of the product of bidimensional disease qualifies as progression. An increase in the number of metastatic lesions on bone scan qualifies as progression. * All patients must have a minimum PSA of 1ng/ml. * Patients on antiandrogens should be discontinued from flutamide or nilutamide for at least 4 weeks and bicalutamide for 8 weeks. If progression is documented as below prior to this time interval, patients are eligible. * Patients must have a performance status of \< 2 (ECOG). * Patients must have an expected survival from cancer or co-morbidity of at least three months. * Patients may receive no concurrent chemotherapy, immunotherapy or ketoconazole. * Patients should not have received prior chemotherapy or radiation within the last 30 days and no Strontium or Samarium within the last 90 days. * Patients must have castrate serum testosterone levels (\< 30ng/dl). For patients who are medically castrated, luteinizing hormone releasing hormone a…